Pfizer Says CIFFREO Phase 3 Study Evaluating Investigational Mini-Dystrophin Gene Therapy, Fordadistrogene Movaparvovec, In Ambulatory Patients With Duchenne Muscular Dystrophy, Did Not Meet Its Primary Endpoint
Portfolio Pulse from Benzinga Newsdesk
Pfizer announced that its Phase 3 CIFFREO study evaluating the investigational mini-dystrophin gene therapy, Fordadistrogene Movaparvovec, in ambulatory patients with Duchenne Muscular Dystrophy did not meet its primary endpoint.
June 12, 2024 | 8:31 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Pfizer's Phase 3 CIFFREO study for the investigational gene therapy Fordadistrogene Movaparvovec in Duchenne Muscular Dystrophy patients did not meet its primary endpoint, which could negatively impact investor sentiment and short-term stock price.
The failure to meet the primary endpoint in a Phase 3 study is a significant setback for Pfizer's investigational gene therapy, likely leading to negative investor sentiment and a short-term decline in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100